Pfizer Inc. (BVL:PFEUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 468.38B -5.2% |
| Revenue (ttm) | 220.96B +1.4% |
| Net Income | 26.14B -5.0% |
| EPS | 4.58 -5.1% |
| Shares Out | n/a |
| PE Ratio | 17.92 |
| Forward PE | 8.39 |
| Dividend | 6.01 (7.29%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 468 |
| Open | 24.25 |
| Previous Close | 24.20 |
| Day's Range | 24.25 - 24.26 |
| 52-Week Range | 23.72 - 28.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC
Pfizer (PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda or Key...
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration...
Pfizer price target lowered to $26 from $27 at BofA
BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $27 and keeps a Neutral rating on the shares. Second quarter results are expected to highlight stronger performance…
Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says
A U.S. appeals court on Thursday upheld a ruling for AstraZeneca (AZN) against allegations that its blockbuster lung-cancer drug Tagrisso infringed patents owned by Pfizer (PFE) subsidiary Wyeth, Reut...
Pfizer price target lowered to $28 from $30 at JPMorgan
JPMorgan lowered the firm’s price target on Pfizer (PFE) to $28 from $30 and keeps a Neutral rating on the shares.
Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade
Pfizer stock was hit by a downgrade and a price target cut from a top analyst.
Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low
Rick Ducat points to Pfizer (PFE) as an underperformer in the healthcare sector and greater S&P 500 (SPX). However, shares of the company show some signs of strength that Rick believes sets the stage ...
Pfizer downgraded to Hold from Buy at HSBC
HSBC downgraded Pfizer (PFE) to Hold from Buy with a price target of $28, down from $32. The firm lowered its view of the probability to market of sigvotatug vedotin…
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks be...
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a ...
Pfizer Declares Third-Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company's common stock, payable September 1, 2026, to...
Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer
Pfizer (PFE) announced the U.S. Food and Drug Administration approved Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult ...
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE® (palbociclib) in combination with trastuzumab, with or without pertuzum...
FDA approves Pfizer’s Ibrance combo for metastatic breast cancer
The Food and Drug Administration said it approved Pfizer’s (PFE) Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with...
Pfizer dismissed from US states' drug price-fixing lawsuit
Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
China outpacing Europe in drug innovation and development, Pfizer executive says
China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer executive said on Tuesday.
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...
Pfizer's experimental drug misses main goal of lung cancer trial
Pfizer said on Monday its drug for a type of lung cancer missed the main goal of a late-stage trial.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigationa...
Pfizer CFO Dave Denton to step down, leave company in August
Pfizer said on Thursday that finance chief Dave Denton will step down and leave the company on August 15 to take a role in the consumer goods industry.
Pfizer Announces Chief Financial Officer Transition
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional...
Pfizer CEO warns German investment at risk over drug pricing policies
Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter to Chancellor Friedrich Merz, citing the government's policy proposals that would low...
